ACT-280778 is a L/T calcium channel blocker potentially indicated for the treatment of hypertension and angina pectoris

New Drug Approvals

Abstract Image

ACT-280778

(1R,2R,4R)-2-(2-((3-(4,7-Dimethoxy-1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-5-phenylbicyclo[2.2.2]oct-5-en-2-yl Isobutyrate

Propanoic acid, 2-​methyl-​, (1R,​2R,​4R)​-​2-​[2-​[[3-​(4,​7-​dimethoxy-​1H-​benzimidazol-​2-​yl)​propyl]​methylamino]​ethyl]​-​5-​phenylbicyclo[2.2.2]​oct-​5-​en-​2-​yl ester

isobutyric acid (1R,2R,4R)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester

Actelion Pharmaceuticals Ltd innovator

C33 H43 N3 O4 1075744-31-8

bis-MALEATE SALT  1537197-53-7

Chiral bicyclic benzimidazole 1 (ACT-280778) is a L/T calcium channel blocker potentially indicated for the treatment of hypertension and angina pectoris 

 Many cardiovascular disorders have been associated with a ‘calcium overload’ resulting from an abnormal elevated calcium influx through the plasma membrane of cardiac and vascular smooth muscle cells. There are 3 major pathways through which extracellular calcium can enter these cells: 1 ) receptor-activated calcium channels, 2) ligand-gated calcium channels and 3) voltage-operated calcium channels (VOCs). 0 VOCs have been classified into 6 main categories: L (Long-lasting), T (Transient), N (Neuronal), P (Purkinje cells), Q (after P) and R…

View original post 3,748 more words

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s